Cited in:


This article has been cited by:

  1. 1
    José Antonio Carrión, Elena Gonzalez-Colominas, Montserrat García-Retortillo, Nuria Cañete, Isabel Cirera, Susanna Coll, Maria Dolors Giménez, Carmen Márquez, Victoria Martin-Escudero, Pere Castellví, Ricard Navinés, Juan Ramon Castaño, Josep Anton Galeras, Esther Salas, Felipe Bory, Rocío Martín-Santos, Ricard Solà, A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C, Journal of Hepatology, 2013, 59, 5, 926


  2. 2
    Joachim Lupberger, Daniel J. Felmlee, Thomas F. Baumert, Interferon-lambda polymorphisms and hepatitis C virus clearance revisited, Hepatology, 2013, 58, 1
  3. 3
    E. B. Tapper, N. H. Afdhal, Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3, Journal of Viral Hepatitis, 2013, 20, 10
  4. 4
    Felix Stickel, Mathias Worni, Isabelle Pache, Darius Moradpour, Beat Helbling, Jan Borovicka, Tilman J Gerlach, Optimizing Ribavirin Exposure by Therapeutic Drug Monitoring Improves Treatment Response in Patients With Chronic Hepatitis C Genotype 1, The American Journal of Gastroenterology, 2013, 108, 7, 1176


  5. 5
    Paul J. Clark, Andrew J. Muir, Lost in translation? IL28B's discovery and the journey back to the patient, Hepatology, 2012, 56, 1